Latest Insider Transactions at Apogee Therapeutics, Inc. (APGE)
This section provides a real-time view of insider transactions for Apogee Therapeutics, Inc. (APGE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apogee Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apogee Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2024
|
Mark C. Mc Kenna Director |
BUY
Open market or private purchase
|
Direct |
20,000
+44.23%
|
$980,000
$49.43 P/Share
|
|
Dec 11
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,540
-0.87%
|
$222,460
$49.31 P/Share
|
|
Dec 11
2024
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,815
+0.69%
|
$39,930
$22.86 P/Share
|
|
Dec 04
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.56%
|
$690,000
$46.84 P/Share
|
|
Dec 04
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-2.49%
|
$306,590
$46.07 P/Share
|
|
Nov 06
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.55%
|
$885,000
$59.55 P/Share
|
|
Nov 06
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.22%
|
$393,235
$59.43 P/Share
|
|
Oct 02
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-1.44%
|
$2,240,000
$56.41 P/Share
|
|
Oct 02
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.19%
|
$373,240
$56.51 P/Share
|
|
Sep 04
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-1.4%
|
$1,880,000
$47.75 P/Share
|
|
Sep 04
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.16%
|
$313,255
$47.78 P/Share
|
|
Aug 23
2024
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-2.9%
|
$288,000
$48.26 P/Share
|
|
Aug 07
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-0.91%
|
$1,640,000
$41.36 P/Share
|
|
Aug 07
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,335
-0.83%
|
$300,735
$41.37 P/Share
|
|
Jul 05
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.01%
|
$555,000
$37.26 P/Share
|
|
Jul 03
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,995
-1.0%
|
$221,815
$37.73 P/Share
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
55,913
+2.66%
|
-
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
55,913
-100.0%
|
-
|
|
Jan 29
2024
|
Fairmount Funds Management LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
102,332
+50.0%
|
-
|
|
Jan 29
2024
|
Fairmount Funds Management LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
892,529
-100.0%
|
-
|
|
Jul 13
2023
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
2,941,176
+50.0%
|
$49,999,992
$17.0 P/Share
|
|
Jul 13
2023
|
Nimish P Shah Director |
BUY
Open market or private purchase
|
Indirect |
1,750,000
+50.0%
|
$29,750,000
$17.0 P/Share
|